Sign up to save your podcasts
Or
Share Enhanced Solid Tumor NGS Panel Broadens Genetic-Variants Detection: Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Enhanced Solid Tumor NGS Panel Broadens Genetic-Variants Detection: Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S.
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' augmented MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted cancer therapy.
(00:31)
Can you tell us a little about yourself and your background — Beth?
(01:24)
Stephanie, what about you?
(01:42)
Dr. Jenkins, a little bit about yourself and your background, please?
(02:25)
Could you provide a brief overview of the new MayoComplete Solid Tumor assay and the enhancements we've provided?
(04:02)
What changes did you incorporate into the test?
(04:57)
Why are copy number variants and loss of heterozygosity important, and how are they used in patient care?
(07:12)
Does including these genes guide patient care in a more valuable way?
(07:51)
What alternative test options are available and how do they compare to the MayoComplete Solid Tumor Panel?
(10:27)
Is having many options available in a one-stop shop important to help guide patient management?
(11:57)
Do you have anything else you'd like to add about the MCSTP enhancements and what the new test assay will deliver in terms of clinical utility or patient care?
View all episodes
By Mayo Clinic Laboratories
5
2121 ratings
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' augmented MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted cancer therapy.
(00:31)
Can you tell us a little about yourself and your background — Beth?
(01:24)
Stephanie, what about you?
(01:42)
Dr. Jenkins, a little bit about yourself and your background, please?
(02:25)
Could you provide a brief overview of the new MayoComplete Solid Tumor assay and the enhancements we've provided?
(04:02)
What changes did you incorporate into the test?
(04:57)
Why are copy number variants and loss of heterozygosity important, and how are they used in patient care?
(07:12)
Does including these genes guide patient care in a more valuable way?
(07:51)
What alternative test options are available and how do they compare to the MayoComplete Solid Tumor Panel?
(10:27)
Is having many options available in a one-stop shop important to help guide patient management?
(11:57)
Do you have anything else you'd like to add about the MCSTP enhancements and what the new test assay will deliver in terms of clinical utility or patient care?
More shows like Answers from the Lab
View all
JAMA Editors' Summary
129 Listeners
This American Life
90,603 Listeners
Fresh Air
38,168 Listeners
Nutrition Diva
1,705 Listeners
JAMA Clinical Reviews
487 Listeners
Science Vs
11,976 Listeners
Mayo Clinic Talks
272 Listeners
The Daily
110,932 Listeners
Up First from NPR
55,862 Listeners
This Podcast Will Kill You
16,802 Listeners
The Indicator from Planet Money
9,520 Listeners
The Peter Attia Drive
7,951 Listeners
Lab Medicine Rounds
16 Listeners
Morning Brew Daily
2,944 Listeners
AMA Update
99 Listeners